GV20 Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- GV20 Therapeutics's estimated annual revenue is currently $2.8M per year.
- GV20 Therapeutics's estimated revenue per employee is $100,500
- GV20 Therapeutics's total funding is $2.9M.
Employee Data
- GV20 Therapeutics has 28 Employees.
- GV20 Therapeutics grew their employee count by 33% last year.
GV20 Therapeutics's People
| Name | Title | Email/Phone |
|---|
GV20 Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is GV20 Therapeutics?
GV20 Therapeutics is the US branch of GV20 Oncotherapy. The company utilizes high throughput functional genomics and AI approaches to identify novel cancer immunology drug targets, and discover and develop effective antibody drugs in cancer. GV20's proprietary antibody drug discovery engine has helped establish a solid portfolio of immuno-oncology antibody drug candidates for cancer treatment.
keywords:N/A
$2.9M
Total Funding
28
Number of Employees
$2.8M
Revenue (est)
33%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.3M | 28 | 8% | N/A |
#2 | $2.8M | 28 | N/A | N/A |
#3 | $4M | 28 | N/A | N/A |
#4 | $2.7M | 28 | N/A | N/A |
#5 | $2.8M | 28 | N/A | N/A |